BIOMARIN PHARMACEUTICAL INC

Listed Company

BMRNCIK 0001048477NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$3.22B

Net Income

$348.90M

Total Assets

$7.59B

Equity

$6.09B

Shares Out

193.28M

Op. Cash Flow

$827.99M

BMRN$59.58+2.11% · past yearDBEQ Basic

Daily closing prices

Business

BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company focused on developing and commercializing medicines for genetically defined conditions. The company markets eight commercial therapies including VOXZOGO for achondroplasia and enzyme replacement therapies for mucopolysaccharidosis and other lysosomal storage disorders. BioMarin operates through two primary business units—Skeletal Conditions and Enzyme Therapies—with a pipeline of clinical and preclinical candidates addressing genetic disorders with significant unmet medical need. The company manufactures active pharmaceutical ingredients at facilities in California and Ireland, distributes products directly in the U.S., Europe and select markets, and partners with distributors and Sanofi for specific territories and products.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	3,221	2,854	2,419	2,096	1,846
Cost of sales	717	580	532	503	471
Research and development	922	747	747	650	629
Selling, general and administrative	1,153	1,009	892	823	759
Intangible asset amortization	19	43	62	67	—
Gain on sale of nonfinancial assets	0	−10	0	−108	0
Total operating expenses	2,812	2,370	2,233	1,935	1,929
INCOME FROM OPERATIONS	409	484	186	161	−82
Interest income	75	75	58	18	10
Interest expense	−11	−13	−17	−16	—
Other income (expense), net	9	−5	−38	−13	12
INCOME BEFORE INCOME TAXES	482	542	189	150	−75
Provision for income taxes	134	115	21	8	−11
NET INCOME	349	427	168	142	−64
EARNINGS PER SHARE, BASIC (in dollars per share)	1.82	2.25	0.89	0.76	−0.35
EARNINGS PER SHARE, DILUTED (in dollars per share)	1.8	2.21	0.87	0.75	−0.35
Weighted-average common shares outstanding, basic (in shares)	192	190	188	185	183
Weighted average common shares outstanding, diluted (in shares)	197	197	192	189	183

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	1,312	943	755	725	587
Short-term investments	249	195	319	567	427
Accounts receivable, net	908	661	634	461	373
Inventory	1,299	1,233	1,107	894	777
Other current assets	186	202	141	105	110
Total current assets	3,953	3,232	2,956	2,751	2,274
Long-term investments	492	521	611	334	508
Property, plant and equipment, net	953	1,043	1,066	1,073	1,035
Intangible assets, net	214	255	295	339	389
Goodwill	196	196	196	196	196
Deferred tax assets	1,509	1,489	1,546	1,505	1,450
Other assets	277	251	172	176	152
Total assets	7,594	6,989	6,842	6,375	6,005
Accounts payable and accrued liabilities	759	607	683	573	498
Total current liabilities	759	607	1,177	589	546
Long-term convertible debt, net	597	595	593	1,083	1,079
Other long-term liabilities	151	129	120	100	98
Total liabilities	1,507	1,331	1,890	1,772	1,739
Common stock, $0.001 par value: 500,000,000 shares authorized; 192,300,101 and 190,761,349 shares issued and outstanding, respectively	192,000	191,000	189,000	186,000	184,000
Additional paid-in capital	5,957	5,802	5,612	5,405	5,192
Company common stock held by the Nonqualified Deferred Compensation Plan	−11	−11	−10	−9	−10
Accumulated other comprehensive income (loss)	−13	62	−29	−4	14
Retained earnings (accumulated deficit)	154	−195	−622	−789	−931
Total stockholders equity	6,087	5,658	4,952	4,603	4,266
Total liabilities and stockholders equity	7,594	6,989	6,842	6,375	6,005

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	80	96	104	102	108
Non-cash interest expense	3	3	4	4	4
Accretion of discount on investments	−5	−8	−9	3	5
Stock-based compensation	181	202	207	196	197
Impairment of assets	125	20	39	0	0
ROCTAVIAN inventory write-off	119	0	0	0	0
Deferred income taxes	49	56	−45	−52	−16
Unrealized foreign exchange gain	4	−17	28	−14	−2
Acquired in-process research & development expense	221	0	0	—	—
Other	−4	20	−365,000	−2	−3
Accounts receivable, net	−228	−58	−190	−82	66
Inventory	−117	−64	−157	−68	−35
Other current assets	9	−4	−50	8	30
Other assets	−39	−74	−31	−20	−7
Accounts payable and accrued liabilities	66	−32	69	59	16
Other long-term liabilities	15	15	24	7	−3
Net cash provided by operating activities	828	573	159	176	305
Purchases of property, plant and equipment	−103	−85	−97	−121	−96
Maturities and sales of investments	338	633	865	620	691
Purchases of investments	−356	−410	−868	−612	−937
Proceeds from sale of nonfinancial assets	0	10	0	103	0
Purchase of intangible assets	−8	−12	−11	−11	−24
Acquisition, net of cash acquired	−285	0	0	—	—
Other	0	1	0	0	−994,000
Net cash provided by (used in) investing activities	−414	136	−111	−20	−366
Proceeds from exercises of awards under equity incentive plans	14	49	69	69	49
Taxes paid related to net share settlement of equity awards	−56	−78	−76	−54	−46
Repayments of convertible debt	0	−495	0	0	0
Other	−889,000	−3	−12	−3	−398,000
Net cash used in financing activities	−42	−526	−19	−19	−48,000
Effect of exchange rate changes on cash	−3	5	1	32,000	−57,000
NET INCREASE IN CASH AND CASH EQUIVALENTS	369	188	31	137	−62
Cash paid for interest	7	10	10	10	10
Cash paid for income taxes	96	57	73	54	18
Accounts payable and accrued liabilities related to fixed assets	4	4	10	—	—
Accounts payable and accrued liabilities related to intangible assets	1	6	8	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is BIOMARIN PHARMACEUTICAL INC's CIK number?

BIOMARIN PHARMACEUTICAL INC's SEC CIK number is 0001048477 (1048477). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find BIOMARIN PHARMACEUTICAL INC's SEC filings?

All of BIOMARIN PHARMACEUTICAL INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did BIOMARIN PHARMACEUTICAL INC last report earnings?

BIOMARIN PHARMACEUTICAL INC (BMRN) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001048477-26-000006). This is BIOMARIN PHARMACEUTICAL INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is BIOMARIN PHARMACEUTICAL INC's most recent earnings 8-K?

BIOMARIN PHARMACEUTICAL INC's latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001048477-26-000006. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View BIOMARIN PHARMACEUTICAL INC's latest earnings 8-K →
Look up any company's CIK number →